DC Field | Value | Language |
---|---|---|
dc.contributor.author | J H Lee | - |
dc.contributor.author | S Park | - |
dc.contributor.author | S Cheon | - |
dc.contributor.author | J H Lee | - |
dc.contributor.author | S Kim | - |
dc.contributor.author | D Y Hur | - |
dc.contributor.author | T S Kim | - |
dc.contributor.author | Suk Ran Yoon | - |
dc.contributor.author | Y Yang | - |
dc.contributor.author | S I Bang | - |
dc.contributor.author | H Park | - |
dc.contributor.author | H T Lee | - |
dc.contributor.author | D Cho | - |
dc.date.accessioned | 2017-04-19T09:25:34Z | - |
dc.date.available | 2017-04-19T09:25:34Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0014-2980 | - |
dc.identifier.uri | 10.1002/eji.201141597 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/10360 | - |
dc.description.abstract | The active metabolite of vitamin D3, 1α,25(OH)2D3, displays anticancer effects by regulating cell cycle and apoptosis in many cancer cells. However, it has not been determined whether 1α,25(OH)2D3 increases the susceptibility of cancer cells to NK cells. Here, we investigated the anticancer effect of 1α,25(OH)2D3 in human melanoma cell lines by investigating enhancement of NK susceptibility and elucidating the mediator of NK cytotoxicity. 1α,25(OH)2D3-resistant melanoma cells (G-361 and SK-MEL-5) treated with 1α,25(OH)2D3 showed higher susceptibility to NK cells with up-regulation of Fas expression. Furthermore, G-361 cells treated with 1α,25(OH)2D3 showed significantly increased caspase activity. In addition to Fas up-regulation, expression of heat shock protein 60 (Hsp60) was elevated by 1α,25(OH)2D3. Increased expression of Hsp60 by 1α,25(OH)2D3 was related to not only up-regulation of Fas expression but also to NK susceptibility of G-361 cells. Taken together, our data suggest that 1α,25(OH)2D3 acts as an anticancer agent by increasing expression of Fas on the surface of melanoma cells through Hsp60 induction and strengthens caspase sensitivity to Fas-mediated apoptotic pathway by NK cells. 1α,25(OH)2D3 treatment may therefore have a preventive role in melanoma occurrence or potentiate the anticancer effects of NK-cell immune therapy. | - |
dc.publisher | Wiley | - |
dc.title | 1,25-Dihydroxyvitamin D3 enhances NK susceptibility of human melanoma cells via Hsp60-mediated FAS expression | - |
dc.title.alternative | 1,25-Dihydroxyvitamin D3 enhances NK susceptibility of human melanoma cells via Hsp60-mediated FAS expression | - |
dc.type | Article | - |
dc.citation.title | European Journal of Immunology | - |
dc.citation.number | 10 | - |
dc.citation.endPage | 2946 | - |
dc.citation.startPage | 2937 | - |
dc.citation.volume | 41 | - |
dc.contributor.affiliatedAuthor | Suk Ran Yoon | - |
dc.contributor.alternativeName | 이지 | - |
dc.contributor.alternativeName | 박순영 | - |
dc.contributor.alternativeName | 천소영 | - |
dc.contributor.alternativeName | 이주 | - |
dc.contributor.alternativeName | 김성한 | - |
dc.contributor.alternativeName | 허대 | - |
dc.contributor.alternativeName | 김태 | - |
dc.contributor.alternativeName | 윤석란 | - |
dc.contributor.alternativeName | 양율희 | - |
dc.contributor.alternativeName | 방사 | - |
dc.contributor.alternativeName | 박현정 | - |
dc.contributor.alternativeName | 이훈 | - |
dc.contributor.alternativeName | 조대호 | - |
dc.identifier.bibliographicCitation | European Journal of Immunology, vol. 41, no. 10, pp. 2937-2946 | - |
dc.identifier.doi | 10.1002/eji.201141597 | - |
dc.subject.keyword | 1α,25(OH)2D3 | - |
dc.subject.keyword | Fas | - |
dc.subject.keyword | HSP | - |
dc.subject.keyword | Melanoma | - |
dc.subject.keyword | NK cells | - |
dc.subject.local | 1α,25(OH)2D3 | - |
dc.subject.local | FAS | - |
dc.subject.local | Fas | - |
dc.subject.local | fas | - |
dc.subject.local | HSP | - |
dc.subject.local | HSPs | - |
dc.subject.local | Melanoma | - |
dc.subject.local | melanoma | - |
dc.subject.local | NK cells | - |
dc.subject.local | NK cell | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.